Michael Buschle
Director/Board Member chez VICORE PHARMA HOLDING AB
Profil
Michael Buschle is the founder of Intercell AG, which was founded in 1997.
He held the title of Chief Scientific Officer at Intercell AG.
Currently, Dr. Buschle holds two positions.
He is a Director at Vicore Pharma Holding AB since 2023 and a Venture Partner at HBM Partners AG since 2017.
Dr. Buschle's former positions include being an Independent Director at Y-mAbs Therapeutics, Inc. from 2017 to 2018 and Chief Scientific Officer at Glenmark Pharmaceuticals Ltd.
Postes actifs de Michael Buschle
| Sociétés | Poste | Début |
|---|---|---|
| VICORE PHARMA HOLDING AB | Director/Board Member | 01/01/2023 |
HBM Partners AG
 HBM Partners AG Investment ManagersFinance HBM Partners AG (HBM-P) was established in 2001 as an independent provider of investment advisory services with headquarters in Zug, Switzerland. HBM-P's field of expertise comprises global human medicine, biotechnology, medical technology and related sectors. The firm primarily advises HBM BioVentures AG and HBM BioCapital via their Cayman Islands-based, wholly-owned subsidiary, HBM Partners (Cayman) Ltd., which acts as the investment manager for the HBM funds. They rely on the services of an external consultant to analyze investment opportunities in the US. | Private Equity Investor | 01/01/2017 |
Anciens postes connus de Michael Buschle
| Sociétés | Poste | Fin |
|---|---|---|
| Y-MABS THERAPEUTICS, INC. | Director/Board Member | 11/12/2018 |
| GLENMARK PHARMACEUTICALS LIMITED | Chief Tech/Sci/R&D Officer | - |
Intercell AG
 Intercell AG Pharmaceuticals: MajorHealth Technology Intercell AG engages in the research, development, manufacture, and marketing of novel vaccines for the prevention and treatment of infectious diseases. Its products include Japanese encephalitis vaccine, Pseudomonas vaccine, Clostridium difficile vaccine, tuberculosis vaccine, and pandemic influenza vaccine patch. Its technology platforms involve patch-based delivery system and proprietary human monoclonal antibody discovery system. The company was founded by Alexander von Gabain, Max Birnstiel, Michael Buschle, Walter Schmidt, and Aaron Hirsh on December 3, 1997 and is headquartered in Vienna, Austria. | Founder | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| GLENMARK PHARMACEUTICALS LIMITED | Health Technology |
| VICORE PHARMA HOLDING AB | Health Technology |
| Y-MABS THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
HBM Partners AG
HBM Partners AG Investment ManagersFinance HBM Partners AG (HBM-P) was established in 2001 as an independent provider of investment advisory services with headquarters in Zug, Switzerland. HBM-P's field of expertise comprises global human medicine, biotechnology, medical technology and related sectors. The firm primarily advises HBM BioVentures AG and HBM BioCapital via their Cayman Islands-based, wholly-owned subsidiary, HBM Partners (Cayman) Ltd., which acts as the investment manager for the HBM funds. They rely on the services of an external consultant to analyze investment opportunities in the US. | Finance |
Intercell AG
Intercell AG Pharmaceuticals: MajorHealth Technology Intercell AG engages in the research, development, manufacture, and marketing of novel vaccines for the prevention and treatment of infectious diseases. Its products include Japanese encephalitis vaccine, Pseudomonas vaccine, Clostridium difficile vaccine, tuberculosis vaccine, and pandemic influenza vaccine patch. Its technology platforms involve patch-based delivery system and proprietary human monoclonal antibody discovery system. The company was founded by Alexander von Gabain, Max Birnstiel, Michael Buschle, Walter Schmidt, and Aaron Hirsh on December 3, 1997 and is headquartered in Vienna, Austria. | Health Technology |
